Anivive Lifesciences Announces FDA Approval of Laverdia®, the First Oral Treatment of Its Kind for Canine Lymphoma
Anivive converts Laverdia-CA1 to full FDA approval First FDA-approved product to validate Anivive's AI-enabled development model — from drug repurposing through clinical trial enrollment Affordable oral lymphoma treatment administered at home Additional approvals underway in Australia,...
Anivive converts Laverdia-CA1 to full FDA approval First FDA-approved product to validate Anivive's AI-enabled development model — from drug repurposing through clinical trial enrollment Affordable oral lymphoma treatment administered at home Additional approvals underway in Australia,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.